Ziak E, Sedlmayr P, Sterz F
Wien Med Wochenschr. 1987 Mar 31;137(5-6):123-6.
In a randomized single blind study the efficiency of Trimethoprim as a monosubstance used in the therapy of urinary tract infections was compared to that of Cotrimoxazole. There was a total of 40 patients available 20 of whom were given 2 X 200 mg Trimethoprim throughout 10 days whereas the other 20 patients were given 2 X 160 mg Trimethoprim + 800 mg Sulphamethoxazole in the same period. All patients were hospitalized during treatment. The urine was bacteriologically checked at the beginning of the treatment and after 7, 14 and 28 days respectively. The therapy was equally successful in both groups, both from the clinical and the bacteriological point of view (Trimethoprim 17, Cotrimoxazole 18); a statistically significant difference was not to be proved. In the Trimethoprim group there was one relapse, in the Cotrimoxazole group there were two. Undesirable side effects occurred in both groups with a larger number of them occurring in the Cotrimoxazole group. Cotrimoxazole and Trimethoprim proved equally efficient from a clinical point of view. The proportion of side effects is more favourable for Trimethoprim alone; the cost of therapy is almost 50% lower than that of Cotrimoxazole.
在一项随机单盲研究中，将甲氧苄啶作为单一物质用于治疗尿路感染的疗效与复方新诺明进行了比较。共有40名患者，其中20名患者在10天内每天服用2次200毫克甲氧苄啶，而另外20名患者在同一时期每天服用2次160毫克甲氧苄啶+800毫克磺胺甲恶唑。所有患者在治疗期间均住院。分别在治疗开始时以及治疗7天、14天和28天后对尿液进行细菌学检查。从临床和细菌学角度来看，两组治疗均同样成功（甲氧苄啶组17例，复方新诺明组18例）；未证实有统计学显著差异。甲氧苄啶组有1例复发，复方新诺明组有2例。两组均出现了不良副作用，复方新诺明组出现的副作用更多。从临床角度来看，复方新诺明和甲氧苄啶的疗效相当。单独使用甲氧苄啶时副作用比例更有利；治疗费用比复方新诺明低近50%。
